Electronic cigarettes: peering through the smokescreen

Martin McKee

Health professionals and their patients have every reason to feel confused. One week the WHO issues a position paper calling for strict regulations on electronic nicotine delivery systems (ENDS), more commonly referred to as electronic cigarettes, including restrictions on marketing and a ban on using them in enclosed public spaces. The next week, a group of scientists attracts widespread media attention, with headlines claiming that these products could save 50,000 lives in the UK, although this figure appears nowhere in the corresponding paper. What is one to make of these conflicting messages?

Before reviewing the evidence, some context is necessary. For several decades the tobacco industry, which has been rapidly increasing its share of the market for ENDS sold in the UK, has actively sought to create confusion. It did this very successfully when it sought to block bans on smoking in public places, engaging in a massive campaign of deception. As one of its leading scientists attracts widespread media attention, with headlines claiming that these products can save millions of lives, many apparently from individual users (self-styled as ‘vapers’) whose enthusiasm for these products is such that they seem to spend many hours each day blogging and tweeting their benefits free from the constraints that would be imposed if they were producing official advertisements. More worryingly, they also engage in grossly offensive online attacks on anyone who has the temerity to suggest that ENDS are anything other than an innovation that can save thousands of lives with no risks, with at least one of the most active individuals affiliated to an organisation known to receive tobacco industry funding. Interestingly, despite attacking critics of ENDS for seeking to prevent use of what they see as life-saving devices, some of these bloggers are equally critical of measures such as standardised packaging, that seem to spend many hours each day blogging and tweeting their beneﬁts free from the constraints that would be imposed if they were producing official advertisements. The manufacturers of these products have established a massive online presence, many apparently from individual users (self-styled as ‘vapers’) whose enthusiasm for these products is such that they seem to spend many hours each day blogging and tweeting their benefits free from the constraints that would be imposed if they were producing official advertisements. More worryingly, they also engage in grossly offensive online attacks on anyone who has the temerity to suggest that ENDS are anything other than an innovation that can save thousands of lives with no risks, with at least one of the most active individuals affiliated to an organisation known to receive tobacco industry funding. Interestingly, despite attacking critics of ENDS for seeking to prevent use of what they see as life-saving devices, some of these bloggers are equally critical of measures such as standardised packaging, that really would reduce tobacco induced harm. There are also a few health professionals, largely drawn from the field of nicotine addiction (along with some whose background is in harm reduction among intravenous drug users who see an analogy), who do consider that they may help the particular group of patients they work with and who have been especially vocal in eliciting support for ENDS.

In marked contrast, patients and health professionals can seek advice from any of the number of leading national and global health organisations (box 1) that take a quite different view. Each has undertaken detailed reviews of the available evidence, and while noting that there are still many gaps, reflecting the novelty of these products, the lack of data on the long term effects of deeply inhaling the many flavouring additives and by-products of the heating system, such as a range of metals, and natural suspicions about the rapidly growing presence of the tobacco industry in this market. There is a high level of consensus among these organisations, supported by the systematic review undertaken for the WHO. Based on their assessments, it is possible to offer some answers to questions that might be asked by those contemplating using ENDS.

IF I USE ENDS, WILL I REDUCE MY RISK OF GETTING SMOKING-RELATED DISEASES?

Self-evidently, any health effects of using ENDS will be different from those of smoking as the composition of what is inhaled is different. ENDS do not contain the tar that is the main cause of lung cancer. However, although the advocates of ENDS argue that nicotine is ‘as safe as caffeine’, it is now clear that this is not the case. Its effects may have been obscured by being mixed with tar in cigarettes, but there is growing evidence that it interferes with cellular messaging in ways that are likely to promote cancer development in normal cells and promote tumour growth and spread of existing cancers. ENDS users achieve similar levels of serum cotinine, a marker of nicotine absorption, as is seen with traditional cigarettes. While this is an area where more research is needed, as recognised by the International Agency for Research on Cancer, which has prioritised research on its effects, the precautionary principle would suggest that the advice that pregnant women and breastfeeding mothers should stop smoking should also cover ENDS.

Further concerns relate to the other substances produced by ENDS. Although advocates commonly state that this is only water vapour, this is not the case. ENDS produce levels of ultrapure particles that are similar to those with traditional cigarettes and are associated with release of nitric oxide, suggesting a potential hazard to those at risk of cardiovascular disease. There are also concerns about levels of cytotoxic metals in e-cigarette vapour, produced by heating elements, certain flavourings, such as diacetyl, known to cause lung serious disease, and a range of other chemicals. Advocates of ENDS respond that many of these are present in low levels, but ignore how some users may be inhaling these deep into their lungs for decades and, just because something is considered safe as a food additive, this does not mean that it is safe when inhaled over such a period.

WILL ENDS HELP ME TO QUIT SMOKING?

Although there is a wealth of anecdotes from the advocates of ENDS, the single randomised controlled trial found that ENDS were not significantly better than standard nicotine replacement therapy (NRT). This was despite this trial placing barriers in the path of those randomised to

Correspondence to Professor Martin McKee, European Centre on Health of Societies in Transition, London School of Hygiene and Tropical Medicine, London WC1H 9SS, UK; martin.mckee@lshtm.ac.uk.

McKee M. Postgrad Med J November 2014 Vol 90 No 1069

607
Box 1 Sources of authoritative advice on ENDS

Forum of International Respiratory Societies
‘... electronic nicotine delivery devices should be restricted or banned until more information about their safety is available. If they are allowed, they should be closely regulated as medicines or tobacco products.’

International Union against Tuberculosis and Lung Disease
‘The safety of electronic cigarettes (ECs) or electronic nicotine delivery systems (ENDS) has not been scientifically demonstrated. Adverse health effects for third parties exposed (second-hand exposure) cannot be excluded because the use of electronic cigarettes leads to emission of fine and ultrafine inhalable liquid particles, nicotine and cancer-causing substances into indoor air. The benefits of e-cigarettes have not been scientifically proven. … ENDS could undermine the implementation of the WHO Framework Convention on Tobacco Control.’

American Heart Association
‘There are concerns that e-cigarette use and acceptance of e-cigarettes has the potential to renormalise smoking behaviour, sustain dual use, and initiate or maintain nicotine addiction. Their use also could serve as a gateway to reinitiation of smoking by ex-smokers. Unregulated e-cigarette use also has the potential to erode gains in smoking cessation and smoke-free laws. The AHA [American Heart Association] considers e-cigarettes that contain nicotine to be tobacco products and therefore supports their regulation under existing laws relating to the use and marketing of tobacco products.’

UK Faculty of Public Health
‘What we really need is for electronic cigarettes to be subject to the same controls as tobacco, and e-cigarettes to be treated as a tobacco product, so they cannot be marketed or advertised.’

British Medical Association
‘It is encouraging that the WHO shares our concerns surrounding e-cigarettes and has joined us in calling for stronger regulation… Tighter controls are needed to ensure their use does not undermine current tobacco control measures and reinforces [sic] the normalcy of smoking behaviour.’

NRT, who were required to take a voucher to a pharmacy to obtain it. Given the absence of robust experimental evidence, advocates of ENDS selectively cite observational studies, ignoring those that challenge their arguments. An example is the analogy with smokeless tobacco, or snus, legally sold in Sweden, with frequent use of a graph showing a decline in smoking coinciding with increased use of snus. Yet, disaggregation by sex shows similar changes in smoking by men and women although snus use is extremely rare among women. Another widely cited example uses observational data from England, arguing that the chances of success among those intending to quit are twice as high among those using e-cigarettes compared to those using NRT. Yet, these data show that 80% of those attempting to quit with ENDS in the preceding year were still smoking, hardly a miracle solution, and inexplicably the success rate among those using NRT was lower than among those whose attempts were unassisted. There is also a risk that the use of ENDS may reduce the intention to quit completely. In summary, therefore, this is an area where robust evidence of effectiveness is missing.

WILL I IMPROVE MY HEALTH CHANCES IF I USE ENDS TO HELP ME CUT DOWN ON CIGARETTE?
The risks associated with smoking are non-linear, which is unsurprising given the many toxic substances in tobacco smoke and the diverse organs that they act upon. However, there is now good evidence from a number of cohort studies showing that those cutting their cigarette consumption by more than half obtain few health benefits. The only benefit is a reduction in lung cancer, but even that was smaller than expected. Hence, the evidence is clear. To achieve health benefits it is necessary to quit, not cut down.

SHOULD I TAKE ANY PRECAUTIONS WITH ENDS AND THEIR CONTENTS?
Nicotine is a potent poison. Yet the introduction of ENDS means that concentrated solutions are now being packaged in colourful containers and mixed with flavours that seem designed to appeal to children, such as ‘Gummy Bears’ and bubble gum. In these circumstances, it is unsurprising that there are increasing instances of poisoning of those ingesting the contents of containers. Hence, it is important that ENDS be stored safely, where children and pets are unable to access them.

DISCUSSION
These questions are likely to be the ones most commonly asked of health professionals. However, in their role as advocates for health, it is important that they also take account of the wider context. ENDS manufacturers, now dominated by the major tobacco companies, engage in intensive marketing that seems to be targeted at young people. Thus, a group of US senators has described their sponsorship of sports events and use of flavours and images of celebrities that appeal to young people, with their concerns borne out by studies from the USA and UK. A further concern is the manufacture of what are termed electronic shishas, which contain flavours but no nicotine and so, in many countries, can be sold to children, thereby getting them into the habit of using the same equipment as with ENDS. This marketing also seems to be designed to circumvent advertising bans, for example by the promotion of products looking like cigarettes and packaged in ways that look like established brands. There are also concerns that the use of products that resemble cigarettes (so-called cigalikes) will renormalise the imagery of smoking that has been so effective in movies, where cumulative exposure to scenes of smoking are strongly correlated with youth smoking. Finally, it is clear that the tobacco industry, by presenting itself as part of the solution to smoking related illnesses, is using ENDS to return to the days before the Framework Convention on Tobacco Control when it still had open access to governments.

From a public health perspective, any innovation should prompt three questions. Is it safe, does it work, and who
benefits from its introduction? There are still very large gaps in the evidence but, on the basis of what is known, the answers are that ENDS may be safer than traditional cigarettes but there are many reasons for concern about their safety, especially if they are to be used over many years. They may help some people to quit, but do not seem to be any better than NRT and neither are particularly effective. And the beneficiaries are clearly the tobacco companies, who have shown once again their ability to sow confusion in the eyes of the public and now see a prospect of reinventing themselves as legitimate businesses with whom politicians are no longer ashamed to be seen in public.

Competing interests None.

Provenance and peer review Commissioned; internally peer reviewed.


References


6 Diethelm PA, Riele JC, McKee M. The whole truth and nothing but the truth? The research that Philip Morris did not want you to see. Lancet 2005;366:86–92.


8 Diethelm P, McKee M. Tobacco industry-funded research on standardised packaging: there are none so blind as those who will not see! Tob Control Published Online First: 7 Jul 2014. doi:10.1136/tobaccocontrol-2014-051734


19 Williams M, Villarreal A, Bozhilov K, et al. Metal and silicate particles including nanoparticles are present in electronic cigarette cartomizer fluid and aerosol. PLOS ONE 2013;8:e57987.


Electronic cigarettes: peering through the smokescreen

Martin McKee

*Postgrad Med J* 2014 90: 607-609 originally published online October 7, 2014
doi: 10.1136/postgradmedj-2014-133029

Updated information and services can be found at:
http://pmj.bmj.com/content/90/1069/607

*These include:*

**References**
This article cites 24 articles, 9 of which you can access for free at:
http://pmj.bmj.com/content/90/1069/607#BIBL

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Editor's choice (141)
- Drugs misuse (including addiction) (35)
- Tobacco related disease (3)

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/